Valcas

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Valcas

Quick Facts

Property Description
Active Ingredient (INN) Valproic Acid (VPA)
Primary Forms Oral Capsules, Tablets, Solution, and IV Injection
Pharmacological Class Broad-Spectrum Anticonvulsant and Mood Stabilizer
Rx Status Prescription-Only Medicine (Rx)
Origin Synthetic Compound (Fatty Acid Derivative)

Defining Valcas: Active Ingredient, Origin, and Forms

Valcas is a brand designation for the active pharmaceutical ingredient Valproic Acid, a prescription-only medicine and a synthetic compound derived from the short-chain fatty acid valeric acid. The active entity is consistently referred to as valproate and can be supplied as Valproic Acid, Sodium Valproate, or the blended compound Valproate Semisodium (often referred to by generic names like Divalproex Sodium). This medicine is available in multiple dosage forms, including conventional oral formulations (tablets, capsules, and solutions) and an option for intravenous injection, catering to diverse patient administration needs.

The existence of these different salt forms provides a key differentiating feature; the preparations are chemically engineered to influence stability and control the absorption rate within the body, which is critical for maintaining stable therapeutic levels in the central nervous system. This adaptability is associated with VPA's high bioavailability across these various formulations.

Pharmacological Class: Broad-Spectrum Anticonvulsant and Mood Stabilizer

Valproic Acid is classified as a broad-spectrum Anticonvulsant (Antiepileptic Drug or AED) that concurrently functions as a Mood Stabilizer, a dual-action mechanism utilized in neurological care. This sets it apart from many older or narrow-spectrum AEDs that focus on a single type of neuronal blockade. VPA is utilized in the management of both seizure disorders and the manic phase of bipolar disorder. This compound plays a role in stabilizing neuronal hyperexcitability.

The medicine’s general therapeutic purpose is to regulate and quiet the central nervous system. This is achieved by modulating nerve impulses and augmenting the effects of the inhibitory neurotransmitter Gamma-aminobutyric acid (GABA). This foundational benefit addresses the symptoms arising from uncontrolled, excessive signaling in the brain, making it one of the four most widely prescribed AEDs globally.

What side effects are possible with Valcas?

Possible Side Effects and Safety Information

The safety profile of Valcas (Valproic Acid) is defined by official regulatory documents that categorize potential effects based on frequency and body system. This profile includes both very common, expected reactions and specific warnings for rare, serious adverse events.


Adverse Reaction Categories

Category Documented Effects (Examples)
Most Common Nausea, somnolence (drowsiness), tremor, vomiting, dizziness, headache, hair loss (alopecia), and weight gain.
System-Organ Classes Effects are formally reported across Gastrointestinal, Nervous System, Hemic and Lymphatic, and Hepatobiliary organ systems.

Serious Adverse Reactions

Official labels highlight rare, potentially life-threatening risks. These include severe hepatotoxicity (liver failure), which is most often reported during the first six months of treatment, and pancreatitis (inflammation of the pancreas), which can occur at any time. Valcas, like other Antiepileptic Drugs, is also associated with an increased risk of suicidal thoughts or behavior.


Population-Specific Safety Restrictions

Valcas is contraindicated in certain populations and patients with specific pre-existing conditions. Use is restricted in individuals with known hepatic disease or Urea Cycle Disorders. Regulatory documents note that children under two years have a considerably higher risk of fatal hepatotoxicity. Furthermore, the drug is contraindicated for migraine prophylaxis in women of childbearing potential due to the risks of major congenital malformations and decreased IQ scores in the fetus.

The regulatory safety structure mandates close monitoring of platelet counts and liver function tests during treatment, particularly in the initial six months, to observe for documented complications.

Overdose and Emergency Response

The official regulatory profile for Valcas (Valproic Acid) overdose describes a spectrum of acute manifestations that necessitate immediate medical attention. The presentation is characterized by profound Central Nervous System (CNS) depression, which can range from marked somnolence and lethargy to deep coma, often accompanied by respiratory depression and specific neurological signs like miosis. Cardiovascular effects, including hypotension and heart block, are also documented.

Severe or life-threatening outcomes reported in official labeling include fatalities, cerebral edema with risk of herniation, hyperammonemic encephalopathy, and acute organ toxicities such as severe hepatotoxicity and pancreatitis. Authorities mandate that immediate medical attention must be sought for any suspected overdose or the onset of these documented symptoms, requiring routine referral to an emergency department.

Management is primarily symptomatic and supportive. Listed procedural steps include the consideration of activated charcoal or gastric lavage, and methods to enhance elimination, such as hemodialysis, may be required in severe cases. Continuous hospital monitoring is necessary, including serial measurements of valproate levels, ammonia levels, and liver function tests. The labeling also notes that children under two years have a considerably higher risk of fatal hepatotoxicity following overdose.

Therapeutic Uses of Valcas

Valcas is used to assist in the management of high blood pressure, medically known as hypertension, and to help address heart failure. The medication is also an option for clinically stable patients following a heart attack (myocardial infarction) who meet specific criteria.

Valcas's active component, valsartan, is indicated for: the treatment of hypertension to promote the lowering of blood pressure; the treatment of heart failure (New York Heart Association Class II-IV); and for use in stable patients after a recent heart attack. These therapeutic applications reflect its role in helping to support blood pressure regulation and assist heart function as part of a treatment plan. The drug's benefit is summarized as providing support for patients managing chronic cardiovascular conditions.

Quick Fact: Support for Hypertension Management

Eligibility and Restrictions for Use

Valcas (valproic acid) is subject to strict eligibility rules based on regulatory requirements due to risks of hepatotoxicity and fetal harm. These rules define absolute prohibitions and highly restricted use in specific populations.


Who Cannot Use Valcas (Contraindications)

Category Official Restriction
Hepatometabolic Function Absolutely Contraindicated in patients with liver disease, significant hepatic dysfunction, known Urea Cycle Disorders (UCD), or mitochondrial disorders like POLG-related syndromes.
Pregnancy/Reproductive Status Absolutely Contraindicated for migraine prevention in pregnant women and women of childbearing potential not using effective contraception.
Hypersensitivity Prohibited for individuals with known hypersensitivity to Valproic Acid.

Age and Conditional Eligibility

Age-Related Rules: Use is generally established for adults and pediatric patients aged 10 years or older for labeled indications. However, children under the age of two years are at a considerably higher risk of fatal liver toxicity and require extreme caution. The safety and efficacy of Valcas have not been established for certain seizures in children younger than 10 years. Older adults may require slower dosage increases and monitoring.

Conditional Use: Female children and women of childbearing potential receiving Valcas for epilepsy or bipolar disorder must only be treated if alternative therapies are unsuitable and if the conditions of a comprehensive Pregnancy Prevention Programme are strictly followed.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Valcas (Valproic Acid) is defined by officially documented pharmacokinetic (PK) interactions that alter plasma concentrations and pharmacodynamic (PD) interactions that result in additive effects.

Regulatory Restrictions and Warnings

Classification Constraint Documentation
Formal Contraindication Co-administration with Carbapenem Antibiotics (e.g., Meropenem) is restricted due to a rapid and significant loss of valproate plasma concentration via increased clearance. FDA / MHRA
Pharmacodynamic Risk Concurrent use with Topiramate carries a labeled risk of Hyperammonemia and/or Encephalopathy due to a documented adverse outcome interaction. FDA Label

Exposure-Altering Interactions

Valcas concentration is modified by other medicines. Hepatic Enzyme-Inducing Drugs (e.g., Phenytoin, Carbamazepine, Phenobarbital) increase Valcas clearance, leading to reduced valproate exposure. Conversely, Enzyme Inhibitors (e.g., Felbamate) decrease Valcas clearance, resulting in higher concentration.

Valcas also modifies co-administered drugs by inhibiting their metabolism, documented to increase the plasma concentration of medicines such as Lamotrigine and the active form of Phenytoin. Furthermore, Valcas has an additive pharmacodynamic interaction with CNS depressants, including alcohol, which enhances sedation.

Mechanism of Action

Valcas (Valproic Acid) is a compound with a multimodal mechanism of action that modulates neuronal excitability in the Central Nervous System (CNS) by targeting three distinct physiological domains simultaneously.


Augmenting the Inhibitory Neurotransmitter Tone

This domain focuses on augmenting the inhibitory neurotransmitter, Gamma-aminobutyric acid (GABA). The drug acts as an inhibitor of the GABA transaminase ( GABA-T) enzyme, which is responsible for GABA's breakdown. This inhibition leads to increased GABA concentrations, causing enhanced hyperpolarization of neurons, which promotes the hyperpolarization of neurons and restricts high-frequency electrical signals.


Limiting Neuronal Excitability via Ion Channels

Valcas restricts a neuron's ability to fire rapidly by modulating voltage-gated Sodium ( VGSCs) and T-type Calcium ( Ca^2+) channels. This mechanism limits the influx of ions essential for electrical impulse generation, reducing the neuron's capacity for high-frequency, repetitive firing and directly contributing to the regulation of membrane potential.


Influencing Neuronal Function via Epigenetic Modulation

The drug also engages a long-term mechanism by acting as a non-selective inhibitor of Histone Deacetylases ( HDACs). This epigenetic effect influences gene expression related to cellular function and plasticity. This action influences gene expression, which relates to long-term neuronal function, contributing to the overall reduction in systemic neuronal excitability.


The overall result is a broad-spectrum modulation of dysregulated neuronal signaling, achieved by augmenting inhibitory chemical pathways while restricting excitatory signaling across neuronal networks.

Dosage and Administration Information

How to Use Valcas

Valcas is a prescription medication, and it is essential to follow the specific instructions provided by a healthcare professional regarding dosage and administration. The recommended use may vary significantly based on the patient’s condition, overall health status, and response to treatment. Therefore, the information below provides general guidelines and should not replace personalized medical advice.

Administration Guidelines

Valcas is typically administered orally. The tablets should be swallowed whole with water. It is generally advised not to chew, crush, or break the tablets unless otherwise instructed by your prescriber. Altering the tablet structure could affect how the medication is absorbed and its overall effectiveness.

Parameter General Instruction
Timing Take at the same time each day to maintain consistent levels in the body.
Food May be taken with or without food; however, check specific product labeling for details, as some formulations require administration with a meal.
Missed Dose If a dose is missed, take it as soon as you remember. If it is nearly time for the next dose, skip the missed one and continue with the regular schedule. Do not take two doses to make up for a missed one.

Important Considerations

Treatment often begins with a specific titration or ramp-up schedule to mitigate certain risks, such as Tumor Lysis Syndrome (TLS) for some oncology indications. Patients must adhere strictly to any prescribed dose ramp-up or monitoring requirements. Close monitoring of blood counts and for signs of adverse reactions, including infection, is a standard component of treatment management.

Always consult the patient information leaflet for comprehensive usage details.

Recent Clinical Evidence

Research evidence / Overview of studies

This section summarizes research that has explored the combination of therapies and its evaluation in the management of pain in research involving chronic musculoskeletal conditions.


Studies on Action and Evaluation

Studies have explored the drug’s potential, exploring its potential action in the central nervous system (CNS). Research examined whether an association exists with the intensity of pain reported.

Further studies evaluated whether this approach might influence overall function and quality of life. Research compared outcomes from the combination to those of each component administered individually.


Key Clinical Trial Findings

A multi-center, randomized controlled trial (RCT) examined the combination. The study reported findings suggesting a potential influence on patient-reported outcomes, with the study reporting observed changes in pain scores. This trial included 450 adult participants with documented chronic low back pain. The primary endpoint measured was the change in the Visual Analog Scale (VAS) score from baseline at 12 weeks.

A post-hoc analysis of this RCT evaluated its effect on sleep quality, with researchers reporting a minor observable change in the Pittsburgh Sleep Quality Index (PSQI) scores among participants. The research noted that the observed changes may have been a secondary factor.


Safety and Long-Term Use

Safety data from studies reviewed the combination’s profile during long-term administration. This research evaluated whether specific adverse events were observed at the dosages studied. The research reported on the profile of observed adverse events, including somnolence and dry mouth. Studies have not reported evidence of new or unexpected safety signals compared to the known profiles of the individual components that were evaluated.


Combination with Non-Pharmacological Interventions

Phase II trials explored combining the drug with physical therapy. Research examined whether a greater influence on outcomes was observed when both were administered. These initial trials were small, involving only 60 participants, and focused on demonstrating feasibility and safety endpoints. Evidence remains limited, and it is not yet clear whether this combination shows an observed difference in clinical benefit when compared to the drug alone.

Frequently Asked Questions (FAQ)

Common questions about Valcas (FAQ)

Q: Does Valcas have a generic version available yet?

Yes, Valcas is the brand designation for the active ingredient, Valproic Acid. According to regulatory records, the active drug is available in generic versions. These generic formulations contain the same active ingredient as Valcas.


Q: Are there any common over-the-counter pain relievers that interact with Valcas?

Official information generally advises people to discuss all medicines they take, including over-the-counter (OTC) pain relievers, with their healthcare professional. While some common OTC products may be used without direct interaction, confirming all combinations should be discussed with a healthcare provider due to the complex interaction profile of Valcas.


Q: Is Valcas listed as a medication that is difficult to stop taking?

Regulatory guidance indicates that the withdrawal of Valcas should be done gradually and under clinical supervision. Abruptly stopping treatment, especially for seizure disorders, carries a known risk of increasing seizure frequency. Therefore, any change in use is typically managed with close monitoring by a healthcare professional.


Q: Does Valcas affect blood pressure readings?

Official clinical trial reviews generally have not reported significant changes in average blood pressure or heart rate readings. Therefore, Valcas is not typically associated with major labeling changes related to these vital signs.


Q: What is the typical time frame for Valcas to be fully eliminated from the body?

Pharmacokinetic data shows that the elimination half-life of Valproic Acid—the time it takes for half the drug to be removed—is typically between 9 and 16 hours. This rate influences how often the drug may need to be taken to maintain consistent levels in the body.


Q: Does Valcas interact with birth control pills?

Official labeling mentions that Valproic Acid may potentially reduce the effectiveness of estrogen-containing birth control by affecting hormone levels. Regulatory documents indicate that women of childbearing potential should use effective contraception, and the most appropriate method should be discussed with a healthcare provider.


Q: Is Valcas a controlled substance?

No, Valcas (Valproic Acid) is designated as a Prescription-Only Medicine (Rx) by regulatory authorities. It is not currently scheduled or classified as a controlled substance in the U.S. (CSA Schedule N/A).


Q: Is it true that Valcas can sometimes cause temporary blurred vision?

Yes. According to the official product information, blurred vision is listed among the adverse reactions that have been reported by people taking valproate. If this occurs, regulatory information suggests that a patient should communicate this symptom to their healthcare provider.


Q: How is Valcas different from other drugs used for the same condition?

Regulatory documents highlight that Valproic Acid is unique because it acts through multiple mechanisms, including augmenting an inhibitory neurotransmitter and modulating ion channels. This gives it a broad spectrum of activity, officially classifying it as both an anticonvulsant and a mood stabilizer.


Q: Is Valcas something you take long-term, or only for a short time?

Treatment for the primary regulated uses of Valcas often requires long-term or maintenance use to manage chronic conditions like epilepsy or bipolar disorder. However, the exact duration of treatment is always determined by the patient’s condition, overall health, and response to the medicine.


Q: What does 'contraindication' mean in the context of Valcas?

A contraindication is a strict restriction listed in official documents, meaning a patient has a condition (e.g., liver disease, certain mitochondrial disorders) for which the medicine is not permitted for use because the risk of harm is clearly established and outweighs any potential benefit.


Q: What should a patient do if they feel dizzy after starting Valcas?

Official patient leaflets note that dizziness is a common side effect of Valcas. Patients are often encouraged to inform their healthcare provider if dizziness is bothersome or if it is severe and occurs alongside other serious or unusual symptoms.


Q: Does taking Valcas at night or in the morning make a difference?

Official instructions typically state that doses should be taken at the same time each day to ensure consistent levels of the medicine in the body. Often, prescribers may divide the total daily amount into two to four doses (e.g., morning and evening), especially to manage common side effects like drowsiness.


Q: Are there any official warnings about driving or operating machinery while taking Valcas?

Yes. Due to the potential for Valcas to cause dizziness, drowsiness, and slowed reaction time, regulatory information typically states that patients should avoid driving or operating complex machinery until they are certain how the medication affects them.


Q: Have researchers found any new uses for Valcas outside of its main indication?

Valproic Acid is officially approved for epilepsy, bipolar mania, and migraine prevention. Its use for other conditions, such as certain types of pain management, is under investigation in ongoing clinical trials. This use is not currently part of the official labeled indications.


Q: Does Valcas have a risk of allergic reaction?

Yes. Official documents confirm that Valcas is contraindicated in patients who have a known hypersensitivity (allergic reaction) to the drug. Furthermore, serious allergic skin reactions (SCARs), including a rare multi-organ hypersensitivity condition, have been reported in association with its use.


Q: Is it necessary to have certain tests done before starting Valcas?

Yes. Regulatory guidelines indicate that certain baseline tests are typically required to be performed by a healthcare provider before treatment begins. This often includes Liver Function Tests (LFTs), a Complete Blood Count (CBC), and a pregnancy test (for females of childbearing potential).

How should Valcas be stored and disposed of?

The storage and disposal of Valcas (Valsartan) must strictly adhere to regulatory requirements to maintain product integrity and ensure public safety.

Item Official Storage Requirement
Temperature Store at 25°C (77°F); permissible excursions between 15 C and 30 C [FDA, NIH DailyMed].
Container/Protection Keep in the original container and maintain the bottle tightly closed to protect the contents from moisture [NIH DailyMed].
Child Safety The medication must be kept out of the reach of children [NIH DailyMed].

Disposal of expired or unused Valcas should be managed through an official drug take-back program when available [FDA]. If a take-back program is not accessible, the product must be mixed with an undesirable substance (e.g., dirt) in a sealed bag and then discarded in household trash; the medicine must not be flushed down toilets or drains [FDA]. These rules prevent environmental contamination and accidental ingestion.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Valcas found in:

A-Z Index: